Key statistics
On Thursday, Novavax Inc (NVV1:STU) closed at 7.74, 126.75% above the 52 week low of 3.41 set on Feb 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.56 |
---|---|
High | 7.78 |
Low | 7.46 |
Bid | 7.61 |
Offer | 7.69 |
Previous close | 7.62 |
Average volume | 4.04k |
---|---|
Shares outstanding | 160.09m |
Free float | 153.08m |
P/E (TTM) | -- |
Market cap | 1.29bn USD |
EPS (TTM) | -2.26 USD |
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Press releases
- Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
- Novavax to Participate in Jefferies London Healthcare Conference
- Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
- U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
- Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024
- Åsa Manelius Named Managing Director of Novavax AB Site
- Åsa Manelius utnämnd till verkställande direktör för Novavax AB:s anläggning
- Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
- Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU
- Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development
More ▼